Inspire Medical Systems (NYSE:INSP) Releases FY 2025 Earnings Guidance

Inspire Medical Systems (NYSE:INSP) updated its FY 2025 earnings guidance on Wednesday. The company provided EPS guidance of 0.900-1.000 for the period, compared to the consensus EPS estimate of 1.010. The company issued revenue guidance of $900.0 million-$910.0 million, compared to the consensus revenue estimate of $903.9 million.

Analysts Set New Price Targets

Several equities research analysts have weighed in on INSP shares. Lake Street Capital set a $150.00 target price on shares of Inspire Medical Systems and gave the company a “buy” rating in a research note on Tuesday, August 5th. Jefferies Financial Group reissued a “hold” rating and issued a $85.00 price objective (down previously from $160.00) on shares of Inspire Medical Systems in a research report on Friday, October 24th. Stifel Nicolaus set a $100.00 target price on Inspire Medical Systems in a research note on Friday, October 24th. JPMorgan Chase & Co. decreased their price target on Inspire Medical Systems from $110.00 to $82.00 and set a “neutral” rating for the company in a research note on Tuesday, November 4th. Finally, Zacks Research upgraded Inspire Medical Systems from a “strong sell” rating to a “hold” rating in a research note on Monday, October 27th. Eight research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $133.88.

Inspire Medical Systems Stock Performance

Shares of INSP stock opened at $90.87 on Thursday. Inspire Medical Systems has a fifty-two week low of $70.77 and a fifty-two week high of $216.01. The firm has a market capitalization of $2.64 billion, a PE ratio of 61.81, a P/E/G ratio of 9.82 and a beta of 1.14. The stock’s 50-day simple moving average is $79.52 and its 200-day simple moving average is $109.94.

Inspire Medical Systems (NYSE:INSP) last issued its quarterly earnings results on Monday, November 3rd. The company reported $0.38 earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.53. Inspire Medical Systems had a net margin of 5.05% and a return on equity of 9.41%. The company had revenue of $224.50 million for the quarter, compared to the consensus estimate of $220.39 million. During the same quarter in the prior year, the company earned $0.60 EPS. Inspire Medical Systems’s quarterly revenue was up 10.5% on a year-over-year basis. Sell-side analysts forecast that Inspire Medical Systems will post 2.16 earnings per share for the current year.

Inspire Medical Systems announced that its board has approved a stock repurchase program on Monday, August 11th that authorizes the company to buyback $200.00 million in outstanding shares. This buyback authorization authorizes the company to purchase up to 8.6% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

Insider Buying and Selling

In other news, CFO Richard Buchholz sold 11,000 shares of the firm’s stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $93.39, for a total transaction of $1,027,290.00. Following the sale, the chief financial officer owned 44,867 shares of the company’s stock, valued at $4,190,129.13. This trade represents a 19.69% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 4.10% of the company’s stock.

Institutional Investors Weigh In On Inspire Medical Systems

Several large investors have recently bought and sold shares of the company. Royal Bank of Canada lifted its stake in Inspire Medical Systems by 16.0% in the 1st quarter. Royal Bank of Canada now owns 32,769 shares of the company’s stock worth $5,220,000 after purchasing an additional 4,528 shares in the last quarter. Integrated Wealth Concepts LLC acquired a new stake in shares of Inspire Medical Systems during the 1st quarter worth about $524,000. Goldman Sachs Group Inc. lifted its stake in Inspire Medical Systems by 57.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 51,422 shares of the company’s stock worth $8,190,000 after acquiring an additional 18,857 shares in the last quarter. Marshall Wace LLP lifted its holdings in Inspire Medical Systems by 3.8% during the 2nd quarter. Marshall Wace LLP now owns 15,905 shares of the company’s stock worth $2,064,000 after buying an additional 577 shares in the last quarter. Finally, Jump Financial LLC acquired a new position in shares of Inspire Medical Systems during the second quarter worth about $931,000. 94.91% of the stock is currently owned by hedge funds and other institutional investors.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.